ESC Premium Access

Evolving role of SGLT2i in HFrEF management

Event: ESC Asia with APSC & AFC 2021
Topic: Pharmacotherapy
Session type: Satellite Symposium
Sponsored by AstraZeneca
Date: 3 December 2021
Time: 07:40 - 08:25

Congress Session

Become an ESC member to access this resource

Become a member

Already a member? Sign in

4 presentations in this session

Welcome and introduction.

Speaker: Professor C. Lam (Singapore, SG)

Emerging evidence for SGLT2i in HFrEF patients.

Speaker: Doctor P. Kumar Sahoo (Bhubaneswar, IN)

SGLT2i in ESC 2021 HF management guideline - clinical implication.

Speaker: Doctor J. Kang (Seoul, KR)

Discussion and live Q&A.


3 speakers from this session

Professor Carolyn Sp Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
102 presentations

Doctor Prasant Kumar Sahoo

, Bhubaneswar (India)
1 presentation
0 follower

Doctor Jeehoon Kang

Seoul National University, Seoul (Korea (Republic of))
1 presentation
0 follower

Related content

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk